The abstract is read at the publisher; the summary is JClub's.
In high-grade serous ovarian cancer, liver metastases show marked clonal and microenvironmental heterogeneity, but direct molecular evidence from hepatic lesions remains sparse.
- Why it matters: Treating liver involvement as one entity may overlook differences between liver-surface implants and parenchymal deposits, including lesion-specific evolution and treatment-associated cell states.
- What they did: This Mini Review outlines combining germline susceptibility, somatic change, spatial biology, and artificial intelligence to distinguish constitutional from tumor-acquired variation and map programs to spatial compartments.
- The result: AI integration is positioned to generate and test reproducible hypotheses, with paired sampling, orthogonal assays, patient-level validation, and decision-specific clinical endpoints needed before guiding liver-directed therapy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.